

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UNISOUND AI TECHNOLOGY CO., LTD.

雲知聲智能科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9678)

VOLUNTARY ANNOUNCEMENT SIGNED MULTIPLE LLM PROJECTS AT GRADE 3 CLASS A HOSPITALS

This announcement is made by Unisound AI Technology Co., Ltd. (the “**Company**”) on a voluntary basis to inform the shareholders and potential investors of the Company of its latest business developments.

Following the official launch of U2, a new-generation general-purpose foundation large language model (LLM), the Company achieved a significant leap forward in the comprehensive capabilities of general-purpose foundation LLMs, substantially accelerating the iteration efficiency of vertical domain models. Recently, leveraging the healthcare data assets it has accumulated over many years and its deep insights into various business scenarios in healthcare, the Company released the “U2-Med Tri-Medical LLM”, the industry’s first professional LLM for the medical, medical insurance (including commercial insurance), and pharmaceutical sectors, further consolidating the Company’s leading advantage in LLMs capabilities in the pan-medical field.

Leveraging the above competitive advantages, the Company has recently successively won AI-driven healthcare development projects from several leading domestic Grade 3 Class A hospitals, including Beijing You An Hospital Affiliated to Capital Medical University, Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), and Nanjing Tongren Hospital and other regional benchmark medical institutions. The implementation of these benchmark projects not only continues to consolidate the Company’s core competitive advantages in the high-end market, but also marks the entry of the its medical LLMs commercialization into a new phase of scalable replication. The corresponding orders fully demonstrate that the Company has established a mature, standardized, and rapidly scalable and replicable implementation and delivery system regarding medical LLMs, which can quickly adapt to the intelligent development needs of different departments and hospitals. It has set an example for the commercialization of medical LLMs in China.

In the future, the Company will continue to deepen the application and innovation of LLMs in the pan-medical field, leveraging its self-developed core AI technology foundation to unlock significant industrial value from high-token applications and promoting the evolution of medical LLMs into industrial infrastructure. Meanwhile, the Company will further enhance its standardized and scalable delivery capabilities, empower medical institutions to improve quality and efficiency, and consolidate its leading position in the commercialization of medical LLMs.

By Order of the Board
Unisound AI Technology Co., Ltd.
Dr. Huang Wei
Executive Director and Chief Executive Officer

Beijing, the PRC
July 17, 2026

As at the date of this announcement, the Board of Directors of the Company comprises: (i) Dr. Liang Jia'en, Dr. Huang Wei, Dr. Kang Heng, Dr. Li Xiaohan and Dr. Liu Shengping as executive Directors; and (iii) Mr. Hu Jianjun, Dr. Fan Jian, Dr. Jin Huihua and Dr. Zhang Kun as independent non-executive Directors.